COVID-19 Pharma Sector Pipeline Portfolio of Companies Involved in the COVID-19 Disease Space - ResearchAndMarkets.com

DUBLIN--()--The "Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast" report has been added to ResearchAndMarkets.com's offering.

This report contains a summary of the consensus forecasts available in the 'Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19'. Despite the rapid development of COVID-19 therapies being developed, the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available.

This 27-page report gives important, expert insight you won't find in any other source. Seven figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines.

This report is required reading for:

  • Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
  • Companies that are interested in entering the COVID-19 disease space
  • Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space

Key report highlights:

  • Analysis of COVID-19 analyst consensus sales forecasts
  • Overview of Pipeline portfolio of companies involved in COVID-19 disease space
  • Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted drugs

Key Topics Covered:

1 COVID-19 Global Analyst Consensus Sales Forecast

2 Gilead Sciences Inc.

2.1 Gilead Sciences' Pipeline

2.2 Global Analyst Consensus Sales Forecast - Gilead Sciences' Remdesivir

3 CanSino Biologic Inc.

3.1 CanSino Biologic Pipeline

3.2 Global Analyst Consensus Sales Forecast - CanSino Biologic's COVID-19 Vaccine

4 Cytodyn Inc.

4.1 Global Analyst Consensus Sales Forecast - Cytodyn's Leronlimab

4.2 Archived Global Analyst Consensus Sales Forecast - Cytodyn's Leronlimab

5 Key Findings

6 Appendix

6.1 Methodology

6.2 Related Reports

6.3 About the Authors

Companies Mentioned

  • Gilead Sciences Inc.
  • CanSino Biologic Inc.
  • Cytodyn Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gcldlx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900